Accelerating time to market for new therapies
Emerson PKM creates a continuum of process knowledge through the entire drug development lifecycle, from early-stage research through late-state commercial manufacturing, and provides a structured repository and collaboration model for recipes that facilitate drug development. PKM enables global sites, cross-functional teams, and contract manufacturing organizations (CMO) to work together to scale recipes and execute technology transfers.
Learn how a digital solution for recipe management can reduce time to market
Learn how a common platform for information exchange can accelerate tech transfers by digitizing the drug development process, including recipes, workflows, and scaling instructions.
Learn how a digital solution for recipe management can reduce time to market
Learn how a common platform for information exchange can accelerate tech transfers by digitizing the drug development process, including recipes, workflows, and scaling instructions.
Drag-and-drop user interface that simplifies and standardizes the creation of products and processes in conformance to ISA-88.
Structured, configuration-driven approach to efficiently manage process parameters and calculations without the need for tools such as Microsoft Excel.
Using predictive algorithms, PKM conducts facility fit scenarios and easily identifies gaps through exception reporting.
Eliminate manual data collection and review cycles with automatic document generation in standard formats such as Microsoft Word.
The tech transfer process could be reduced to almost one click by digitizing the associated components, including recipes, workflows, scaling instructions, and process knowledge.
PKM standardizes the product definition, specification structures, and process terminology through the research and clinical phases before the recipe is sent to execution systems such as MES and DES.
Full configurability and workflow management enables a standardized approach across the enterprise facilitating collaboration across internal teams and contract development and manufacturing organizations (CDMO).
Every month lost during technology transfers can cost $80 million
First-to-market drugs average a 6% market-share advantage
A single batch lost can cost up to $3 to $5 million, even patient lives
Poorly executed tech transfers could lead to multi-million penalties
